Literature DB >> 3401356

Nifedipine and platelets in preeclampsia.

P C Rubin1, L Butters, R McCabe.   

Abstract

In addition to its antihypertensive properties, nifedipine inhibits platelet aggregation in vitro. Because increased platelet aggregation is a feature of preeclampsia, we have investigated nifedipine in this condition. Ten women at 31 +/- 2.8 weeks gestation, with blood pressure 162 +/- 18/102 +/- 10 mmHg (despite atenolol 200 mg/day) and proteinuria 2.0 +/- 1.1 g/24 hr, were treated with nifedipine. Pregnancies were prolonged by 17 +/- 15 days (range 5 to 56). Blood pressure was controlled in eight of the ten patients, final values before delivery being 142 +/- 16/89 +/- 12 mmHg (P less than 0.02). Platelet count rose in all women from 190 +/- 80 to 261 +/- 78 X 10(9)/1 (P less than 0.001). Nifedipine appears to reverse the thrombocytopenia of pre-eclampsia, in addition to controlling the blood pressure.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3401356     DOI: 10.1093/ajh/1.2.175

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  4 in total

Review 1.  Comparative risk-benefit assessment of drugs used in the management of hypertension in pregnancy.

Authors:  P M Kyle; C W Redman
Journal:  Drug Saf       Date:  1992 May-Jun       Impact factor: 5.606

2.  Effect of nifedipine on Doppler flow velocity waveforms in severe pre-eclampsia.

Authors:  K P Hanretty; M J Whittle; C A Howie; P C Rubin
Journal:  BMJ       Date:  1989-11-11

Review 3.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 4.  [Pharmacologic importance of the combination atenolol/nifedipine in hypertensive patients].

Authors:  A Carré
Journal:  Drugs       Date:  1998       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.